Key takeaways
- Novo Nordisk’s CagriSema outperformed Eli Lilly’s tirzepatide in the Phase III REIMAGINE 5 clinical trial.
- CagriSema combines semaglutide (GLP-1) with cagrilintide (amylin analogue) for dual-action appetite suppression.
- The head-to-head victory positions CagriSema to challenge Zepbound and Mounjaro as the most effective obesity treatment.
- The trial results strengthen the pipeline of next-generation therapies coming to the US cash and telehealth markets.
What happened
Novo Nordisk announced that its next-generation obesity drug, CagriSema, successfully outperformed Eli Lilly’s tirzepatide in the head-to-head Phase III REIMAGINE 5 clinical trial. The study evaluated the safety and efficacy of CagriSema in adults with obesity, demonstrating superior weight loss compared to the current market leader.
Why it matters
For patients navigating the online medical weight-loss space, this head-to-head trial represents a major shift in the future pipeline. Eli Lilly’s tirzepatide (sold brand-name as Zepbound and Mounjaro) has long been considered the most potent weight-loss medication on the market.
By demonstrating that CagriSema can achieve superior weight loss compared to tirzepatide, Novo Nordisk has positioned its combination drug as a highly formidable competitor. This development provides crucial clinical data for cash-pay and insurance buyers looking beyond current first-generation GLP-1 therapies to more effective, next-generation options.
What the data says
The REIMAGINE 5 trial was a direct, head-to-head comparison evaluating CagriSema against tirzepatide over a clinical period. While the complete, granular data set is awaiting full medical conference presentation, the high-level trial results confirmed that CagriSema met its primary endpoint.
CagriSema is a subcutaneous combination of two different mechanisms:
- Semaglutide: The active ingredient in Ozempic and Wegovy, which acts as a GLP-1 receptor agonist.
- Cagrilintide: An investigational long-acting amylin analogue, which targets a different satiety hormone in the brain.
By combining these two distinct pathways, the therapy aims to dual-target hunger centers. In the REIMAGINE 5 study, this dual-action mechanism successfully led to a statistically significant and superior reduction in body weight compared to the dual GLP-1/GIP agonist tirzepatide alone.
How it compares
To understand how CagriSema compares to current options, it is helpful to look at the existing clinical landscape of branded medications:
| Medication | Manufacturer | Class / Mechanism | Average Weight Loss in Key Trials | | :--- | :--- | :--- | :--- | | Wegovy (semaglutide) | Novo Nordisk | GLP-1 receptor agonist | ~15% | | Zepbound (tirzepatide) | Eli Lilly | Dual GLP-1 / GIP receptor agonist | ~20.9% | | CagriSema (semaglutide/cagrilintide) | Novo Nordisk | GLP-1 agonist + Amylin analogue | Superior to tirzepatide (REIMAGINE 5) |
Currently, patients using telehealth services to access weight-loss care often choose between semaglutide vs tirzepatide based on cost, availability, and efficacy. Tirzepatide has generally held the clinical edge for raw weight-loss percentage, though it typically commands a higher price tag.
If CagriSema receives FDA approval, it will re-establish Novo Nordisk at the top of the clinical efficacy ladder. For US buyers shopping via telehealth providers, a future launch of CagriSema could introduce a highly potent option that may eventually challenge the pricing structures of current brand-name medications.
How this fits the bigger picture
The weight-loss drug market is rapidly evolving beyond basic GLP-1 receptor agonists. Novo Nordisk and Eli Lilly are locked in an intensive R&D race to develop compounds that combine multiple mechanisms of action to maximize weight loss while keeping side effects manageable.
This trial result is particularly notable when compared to other recent pipeline developments. For instance, we previously covered how Eli Lilly’s Zepbound-amylin combo drove 23.3% weight loss, but faced significant headwind due to high patient dropout rates caused by tolerability issues. Similarly, we reported on how Boehringer’s survodutide yielded modest 9.8% weight loss in diabetic patients, which also highlighted how crucial tolerability and dropout rates are for cash-pay buyers who cannot afford to abandon an expensive regimen due to severe side effects.
If CagriSema can maintain a tolerable safety profile while outperforming tirzepatide, it will bypass many of the clinical hurdles that have slowed down competitor pipelines. For the consumer, this clinical victory signals that the Novo-Lilly duopoly will continue to drive rapid innovation, ultimately expanding the choices available for medical weight loss.
What happens next
Following the successful readout of the REIMAGINE 5 trial, Novo Nordisk is expected to compile the full data suite from its broader REIMAGINE clinical trial program. The company will use these combined results to submit a regulatory filing to the FDA for the approval of CagriSema.
If approved, CagriSema is expected to launch as a premium, brand-name injectable. In the meantime, patients looking for immediate weight-loss options can use our clinical questionnaire to compare currently available treatments, check what insurance covers, or find the cheapest telehealth GLP-1 options available today.
Disclaimer: CompareRx does not provide medical advice. Always consult a licensed healthcare professional before starting any weight-loss medication or telehealth treatment plan.